Home/Filings/4/0000891839-21-000098
4//SEC Filing

Smith Ernest S. 4

Accession 0000891839-21-000098

CIK 0001205922other

Filed

Apr 1, 8:00 PM ET

Accepted

Apr 2, 4:25 PM ET

Size

11.4 KB

Accession

0000891839-21-000098

Insider Transaction Report

Form 4
Period: 2021-04-02
Smith Ernest S.
SVP, Research & CSO
Transactions
  • Award

    Stock Option (Right to Buy)

    2021-04-02+10,00010,000 total
    Exercise: $2.93Exp: 2031-04-02Common Stock (10,000 underlying)
Holdings
  • Common Stock

    8,000
  • Stock Option (Right to Buy)

    Exercise: $7.10Exp: 2025-12-22Common Stock (40,729 underlying)
    40,729
  • Stock Option (Right to Buy)

    Exercise: $7.10Exp: 2025-12-23Common Stock (5,110 underlying)
    5,110
  • Stock Option (Right to Buy)

    Exercise: $3.90Exp: 2029-03-14Common Stock (8,000 underlying)
    8,000
  • Stock Option (Right to Buy)

    Exercise: $6.07Exp: 2030-02-24Common Stock (8,000 underlying)
    8,000
Footnotes (4)
  • [F1]Exercisable in full as of the date of this report.
  • [F2]This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the March 15, 2019 grant date.
  • [F3]This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the February 25, 2020 grant date.
  • [F4]This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the April 2, 2021 grant date.

Issuer

VACCINEX, INC.

CIK 0001205922

Entity typeother

Related Parties

1
  • filerCIK 0001747769

Filing Metadata

Form type
4
Filed
Apr 1, 8:00 PM ET
Accepted
Apr 2, 4:25 PM ET
Size
11.4 KB